Comments
Caplin Point Laboratories on Monday said its subsidiary has entered into a licence and supply agreement with Baxter Healthcare Corporation for a portfolio of five generic injectables. As a part of the deal, Caplin Steriles, a wholly-owned subsidiary of Caplin Point Laboratories, will out-license five of its injectable Abbreviated New Drug Applications to Baxter Healthcare Corporation. All these ANDAs have been developed in-house and Caplin is keen to license them to Baxter, which has an excellent sales and marketing infrastructure in the US for commercialisation of these products. Shares of Caplin Point closed 0.19 per cent lower at ₹386.55 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.